Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration

Bamias, A; Tzannis, K; Beuselinck, Benoit; Oudard, S; Escudier, B; Diosynopoulos, D; Papazisis, K; Lang, H; Wolter, Pascal; de Guillebon, E; Stravodimos, K; Chrisofos, M; Fountzilas, G; Elaidi, R-T; Dimopoulos, MA; Bamia, C

doi:10.1038/bjc.2013.341

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration

Author:

Bamias, A

Tzannis, K ; Beuselinck, Benoit ; Oudard, S ; Escudier, B ; Diosynopoulos, D ; Papazisis, K ; Lang, H ; Wolter, Pascal ; de Guillebon, E ; Stravodimos, K ; Chrisofos, M ; Fountzilas, G ; Elaidi, R-T ; Dimopoulos, MA ; Bamia, C

Keywords:

Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Renal Cell, Cohort Studies, European Union, Female, Humans, Indoles, Kidney Neoplasms, Male, Middle Aged, Models, Statistical, Neoplasm Metastasis, Predictive Value of Tests, Prognosis, Pyrroles, Survival Analysis, Science & Technology, Life Sciences & Biomedicine, Oncology, renal cancer, prognostic model, targeted therapy, sunitinib, INTERFERON-ALPHA, CANCER, SORAFENIB, SURVIVAL, STRATIFICATION, EFFICACY, FAILURE, TRIAL, Sunitinib, 1112 Oncology and Carcinogenesis, 1117 Public Health and Health Services, Oncology & Carcinogenesis, 3211 Oncology and carcinogenesis

Abstract:

Accurate prediction of outcome for metastatic renal cell carcinoma (mRCC) patients receiving targeted therapy is essential. Most of the available models have been developed in patients treated with cytokines, while most of them are fairly complex, including at least five factors. We developed and externally validated a simple model for overall survival (OS) in mRCC. We also studied the recently validated International Database Consortium (IDC) model in our data sets.